Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Lo Coco

Showing results (111-120 of 204) with videos related to

Pageof 21
Sort By:
Science (New York, N.Y.)|February 9, 2002
Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factorLuciano Di Croce, Veronica A Raker, Massimo Corsaro, et al.
Haematologica|February 13, 2008
NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemiaBrunangelo Falini, Cristina Mecucci, Giuseppe Saglio, et al.
British Journal of Haematology|July 25, 2015
Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxideDavid Sanford, Francesco Lo-Coco, Miguel A Sanz, et al.
Molecular and Clinical Oncology|February 23, 2018
Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemiaCarmelo Gurnari, Paola Panetta, Emiliano Fabiani, et al.
Haematologica|June 1, 2005
TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAILRoberta Riccioni, Luca Pasquini, Gualtiero Mariani, et al.
Blood|September 25, 2008
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetMiguel A Sanz, David Grimwade, Martin S Tallman, et al.
Genes, Chromosomes & Cancer|November 14, 2018
Identification and monitoring of atypical PML/RARA fusion transcripts in acute promyelocytic leukemiaLicia Iaccarino, Mariadomenica Divona, Tiziana Ottone, et al.
Oncotarget|January 12, 2017
Clonal evolution in therapy-related neoplasmsEmiliano Fabiani, Giulia Falconi, Luana Fianchi, et al.
Blood|June 10, 2004
Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemiaFrancesco Lo-Coco, Giuseppe Cimino, Massimo Breccia, et al.
Annals of Hematology|June 29, 2018
Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapyLaura Cicconi, Massimo Breccia, Luca Franceschini, et al.
Pageof 21

Showing results (111-120 of 204) with videos related to

Sort By:
Pageof 21
Science (New York, N.Y.)|February 9, 2002
Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factorLuciano Di Croce, Veronica A Raker, Massimo Corsaro, et al.
Haematologica|February 13, 2008
NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemiaBrunangelo Falini, Cristina Mecucci, Giuseppe Saglio, et al.
British Journal of Haematology|July 25, 2015
Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxideDavid Sanford, Francesco Lo-Coco, Miguel A Sanz, et al.
Molecular and Clinical Oncology|February 23, 2018
Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemiaCarmelo Gurnari, Paola Panetta, Emiliano Fabiani, et al.
Haematologica|June 1, 2005
TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAILRoberta Riccioni, Luca Pasquini, Gualtiero Mariani, et al.
Blood|September 25, 2008
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetMiguel A Sanz, David Grimwade, Martin S Tallman, et al.
Genes, Chromosomes & Cancer|November 14, 2018
Identification and monitoring of atypical PML/RARA fusion transcripts in acute promyelocytic leukemiaLicia Iaccarino, Mariadomenica Divona, Tiziana Ottone, et al.
Oncotarget|January 12, 2017
Clonal evolution in therapy-related neoplasmsEmiliano Fabiani, Giulia Falconi, Luana Fianchi, et al.
Blood|June 10, 2004
Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemiaFrancesco Lo-Coco, Giuseppe Cimino, Massimo Breccia, et al.
Annals of Hematology|June 29, 2018
Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapyLaura Cicconi, Massimo Breccia, Luca Franceschini, et al.
Pageof 21